Rogler Gerhard, Biedermann Luc, Scharl Michael
Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Switzerland.
Swiss Med Wkly. 2018 Mar 22;148:w14599. doi: 10.4414/smw.2018.14599. eCollection 2018.
The exact pathophysiology of inflammatory bowel disease (IBD) is still unknown. However, over the years important insights allowed the development of novel therapeutic approaches that are at the threshold of introduction into clinical practice, or at least in clinical trials. After being first described by Burrill B. Crohn, Crohn's disease, one of the two major forms of IBD, was perceived as an infectious disease. When the concept of autoimmune diseases was formulated, Crohn's disease and ulcerative colitis were thought to be members of this disease group. T cells certainly contribute to the chronification of the intestinal inflammation and targeting T cell migration has been introduced some years ago as a successful therapeutic approach in IBD. Despite the development of successful therapy based on this pathophysiological concept, IBD is no longer seen as a typical autoimmune disease. After the millennium, genome wide association studies on genetic variants and risk factors in these polygenetic diseases have told us a lot about pathogenetic pathways. However, genetic susceptibility explains only up to one third of the cases. Environmental factors also must play a role. Those environmental factors may "transfer" their disease-promoting potential into pathophysiological pathways with the intestinal microbiota as mediator. Hence, the intestinal microbiota has gained much attention as an important factor in disease development. Microbial factors, as well as other direct environmental influences, have been shown to affect epigenetic signatures, intestinal epithelial cells and the innate immune system, providing another important concept on how these diseases originate and can cause repeated flares at the same gut segments even after years of remission and after intermediate complete mucosal healing. Current pathophysiological concepts of IBD not only help us to better understand these diseases and develop new therapies. They also illustrate the evolution of basic scientific concepts over time and that sometimes partially or even largely abandoned concepts persistently influence out current thinking/clinical practice.
炎症性肠病(IBD)的确切病理生理学仍不清楚。然而,多年来的重要见解促使了新治疗方法的发展,这些方法正处于引入临床实践的门槛,或者至少处于临床试验阶段。在被伯里尔·B·克罗恩首次描述后,IBD的两种主要形式之一——克罗恩病,曾被视为一种传染病。当自身免疫性疾病的概念形成时,克罗恩病和溃疡性结肠炎被认为是这个疾病组的成员。T细胞无疑促成了肠道炎症的慢性化,针对T细胞迁移的治疗方法在几年前就已作为IBD的一种成功治疗手段被引入。尽管基于这一病理生理概念开发出了成功的疗法,但IBD不再被视为典型的自身免疫性疾病。进入千禧年后,对这些多基因疾病的基因变异和风险因素进行的全基因组关联研究让我们对致病途径有了很多了解。然而,遗传易感性仅能解释三分之一的病例。环境因素肯定也发挥了作用。这些环境因素可能通过肠道微生物群作为媒介,将其促病潜力“传递”到病理生理途径中。因此,肠道微生物群作为疾病发展中的一个重要因素受到了广泛关注。微生物因素以及其他直接的环境影响已被证明会影响表观遗传特征、肠道上皮细胞和先天免疫系统,这为这些疾病的起源以及为何即使在多年缓解和黏膜完全愈合后仍会在同一肠道节段反复发作提供了另一个重要概念。IBD当前的病理生理概念不仅有助于我们更好地理解这些疾病并开发新疗法。它们还说明了基础科学概念随时间的演变,以及有时部分甚至很大程度上被摒弃的概念如何持续影响我们当前的思维/临床实践。